Hyunjung Lee

Dr. Hyunjung Lee

Chungnam National University, Daejeon, Republic of Korea
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
HKHyeun-Seok Kang
Hyeun-Seok Kang
SGSungwoo Goo
Sungwoo Goo
HLHyunjung Lee
Hyunjung Lee
Jung-woo ChaeJung-woo Chae
Jung-woo Chae
HYHwi-yeol Yun
Hwi-yeol Yun
SJSangkeun Jung
Sangkeun Jung
The identification of optimal drug candidates is very important in drug discovery. Researchers in biology and computational sciences have sought to use machine learning (ML) to efficiently predict drug–target interactions (DTIs). In recent years, according to the emerging usefulness of pretrained models in natural language process (NLPs), pretrained models are being developed for chemical compounds and target proteins. This study sought to improve DTI predictive models using a Bidirectional Encoder Representations from the Transformers (BERT)-pretrained model, ChemBERTa, for chemical compounds. Pretraining features the use of a simplified molecular-input line-entry system (SMILES). We also employ the pretrained ProBERT for target proteins (pretraining employed the amino acid sequences). The BIOSNAP, DAVIS, and BindingDB databases (DBs) were used (alone or together) for learning. The final model, taught by both ChemBERTa and ProtBert and the integrated DBs, afforded the best DTI predictive performance to date based on the receiver operating characteristic area under the curve (AUC) and precision-recall-AUC values compared with previous models. The performance of the final model was verified using a specific case study on 13 pairs of subtrates and the metabolic enzyme cytochrome P450 (CYP). The final model afforded excellent DTI prediction. As the real-world interactions between drugs and target proteins are expected to exhibit specific patterns, pretraining with ChemBERTa and ProtBert could teach such patterns. Learning the patterns of such interactions would enhance DTI accuracy if learning employs large, well-balanced datasets that cover all relationships between drugs and target proteins.

1 January 2019 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
HLHyunjung Lee
Hyunjung Lee
BKBoram Kim
Boram Kim
APAndrew Reyes Padalhin
Andrew Reyes Padalhin
BLByong-taek Lee
Byong-taek Lee

17 March 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
WJWoojin Jung
Woojin Jung
SGSungwoo Goo
Sungwoo Goo
THTaewook Hwang
Taewook Hwang
HLHyunjung Lee
Hyunjung Lee
Young Kuk KimYoung Kuk Kim
Young Kuk Kim
SJSangkeun Jung
Sangkeun Jung
Machine learning techniques are extensively employed in drug discovery, with a significant focus on developing QSAR models that interpret the structural information of potential drugs. In this study, the pre-trained natural language processing (NLP) model, ChemBERTa, was utilized in the drug discovery process. We proposed and evaluated four core model architectures as follows: deep neural network (DNN), encoder, concatenation (concat), and pipe. The DNN model processes physicochemical properties as input, while the encoder model leverages the simplified molecular input line entry system (SMILES) along with NLP techniques. The latter two models, concat and pipe, incorporate both SMILES and physicochemical properties, operating in parallel and with sequential manners, respectively. We collected 5238 entries from DrugBank, including their physicochemical properties and absorption, distribution, metabolism, excretion, and toxicity (ADMET) features. The models’ performance was assessed by the area under the receiver operating characteristic curve (AUROC), with the DNN, encoder, concat, and pipe models achieved 62.4%, 76.0%, 74.9%, and 68.2%, respectively. In a separate test with 84 experimental microsomal stability datasets, the AUROC scores for external data were 78% for DNN, 44% for the encoder, and 50% for concat, indicating that the DNN model had superior predictive capabilities for new data. This suggests that models based on structural information may require further optimization or alternative tokenization strategies. The application of natural language processing techniques to pharmaceutical challenges has demonstrated promising results, highlighting the need for more extensive data to enhance model generalization.

5 December 2019 in Journal of Biomaterials Applications
Verified
Journal Article
Closed access
PDF file
HLHyunjung Lee
Hyunjung Lee
CACeline Dg Abueva
Celine Dg Abueva
APAndrew R Padalhin
Andrew R Padalhin
BLByong-Taek Lee
Byong-Taek Lee
In this study, we prepared an electrospun nanofiber membrane from soya protein isolate (SPI) and polyethylene oxide (PEO) loaded with rat bone marrow-derived mesenchymal stem cells (rBMSC), as a cell-scaffold approach to enhance bone regeneration. Different ratios of SPI:PEO (7:0, 7:1, 7:3, 7:5, and 0:7) was investigated to obtain uniform nanofibers, and crosslinked with EDC/NHS to stabilize the membranes. SPI/PEO membrane (7:3) was found to create more uniform and stable nanofibers at a flow rate of 9 µL/min, spun in a cylindrical collector rotating at 350 r/min, 23 kV DC voltage, and needle tip to collector distance of 13 cm. The loaded rBMSC were pre-differentiated to ensure commitment towards osteoblastic lineage. The SPI/PEO electrospun nanofiber membranes were successful in allowing for cell attachment and growth of the rBMSC and was further investigated in vivo using a rat skull defect model. New bone formation was observed for the optimized SPI/PEO electrospun nanofiber membrane (7:3) with and without rBMSC, but with faster new bone formation for SPI/PEO electrospun nanofiber membrane loaded with rBMSC as compared to SPI/PEO electrospun nanofiber membrane only and control (defect only).

1 November 2018 in Materials & Design
Verified
Journal Article
Closed access
APAndrew Reyes Padalhin
Andrew Reyes Padalhin
BKBoram Kim
Boram Kim
RVReiza D. Ventura
Reiza D. Ventura
HLHyunjung Lee
Hyunjung Lee
SLSeung Jin Lee
Seung Jin Lee
BLByong-taek Lee
Byong-taek Lee

16 October 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
SYSung-Yoon Yang
Sung-Yoon Yang
HLHyunjung Lee
Hyunjung Lee
TBTham Thi Bui
Tham Thi Bui
QTQuyen Tran
Quyen Tran
LNLien Thi Ngo
Lien Thi Ngo
Jung-woo ChaeJung-woo Chae
Jung-woo Chae
Background and Objective: Tofacitinib (TOF), an oral Janus kinase inhibitor used to treat rheumatoid arthritis (RA), is extensively metabolized by cytochrome P450 (CYP) 3A4. Ritonavir (RTV), a protease inhibitor, is commonly used as a pharmacokinetic (PK) enhancer due to its potent CYP3A4 inhibitory effects. Considering the prevalence of comorbidities in RA patients, it is possible to use TOF and RTV concurrently, raising concerns about potential drug–drug interactions (DDIs). The current study aims to assess the potential DDIs between RTV and TOF. Methods: An in vivo rat study was conducted to investigate the impacts of RTV on the PK of TOF. Rats were randomly divided into three groups: vehicle, RTV 10 mg/kg, and RTV 20 mg/kg, each undergoing four days of pretreatment. On the test day, TOF (10 mg/kg) was administered following co-administration of the respective RTV doses. Blood samples were collected at the pre-specified time points. Plasma concentrations of TOF were quantified using liquid chromatography coupled with mass spectrometry, and PK parameters were analyzed using non-compartmental analysis. Results: RTV (10 and 20 mg/kg) increased the area under the curve of TOF by 2.53-fold (95% CI: 1.64–3.43) and 5.39-fold (95% CI: 4.47–6.33), respectively, and the maximum concentration by 1.47-fold (95% CI: 0.99–2.00) and 2.86-fold (95% CI: 2.39–3.37), respectively. Whereas the half-life (t1/2) remained unchanged. Conclusions: RTV substantially increased TOF exposure in rats. These results suggest the need for dose adjustments of TOF during co-administration with RTV in clinical settings. Further clinical research is needed to confirm these findings.